Why AbbVie Stock Flopped on Friday
's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release, and investors expressed their displeasure with it by selling out of the stock. It declined by more than 4% in price that trading session, contrasting unfavorably with the 0.3% gain of the S 500 index.
For its third quarter, AbbVie reaped just under $15.78 billion in revenue, which was 9% higher on a year-over-year basis. This was led by the company's enviable collection of blockbuster drugs; Skyrizi experienced a 47% increase in net revenue to $4.7 billion, for example, while Rinvoq advanced 35% to generate $2.2 billion for the top line.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
Die Community liebt AbbVie Inc.: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für AbbVie Inc. mit einem Kursziel von 209 € im Vergleich zu 190.4 €.
